期刊
CELL REPORTS
卷 30, 期 10, 页码 3478-+出版社
CELL PRESS
DOI: 10.1016/j.celrep.2020.02.059
关键词
-
类别
资金
- JSPS KAKENHI [24590279, 15K08177, 18K06855, 24590357, 15K08279, 18K06959]
- Life Science Foundation of Japan
- Mitsui Sumitomo Insurance Welfare Foundation of Japan
- Stowers Institute for Medical Research, United States
- Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) from AMED, Japan [JP18am0101107]
- Kochi University Hospital Director's Discretionary Expense Research Grant
- Grants-in-Aid for Scientific Research [18K06855, 15K08279, 15K08177, 24590279, 18K06959, 24590357] Funding Source: KAKEN
Alzheimer's disease (AD) is a progressive neurode-generative disease caused by accumulations of A beta peptides. Production and fibrillation of A beta are downregulated by BRI2 and BRI3, which are physiological inhibitors of amyloid precursor protein (APP) processing and A beta oligomerization. Here, we identify nuclear receptor binding protein 1 (NRBP1) as a substrate receptor of a Cullin-RING ubiquitin ligase (CRL) that targets BRI2 and BRI3 for degradation. Moreover, we demonstrate that (1) dimerized NRBP1 assembles into a functional Cul2- and Cul4A-containing heterodimeric CRL through its BC-box and an overlapping cryptic H-box, (2) both Cul2 and Cul4A contribute to NRBP1 CRL function, and (3) formation of the NRBP1 heterodimeric CRL is strongly enhanced by chaperone-like function of TSC22D3 and TSC22D4. NRBP1 knockdown in neuronal cells results in an increase in the abundance of BRI2 and BRI3 and significantly reduces A beta production. Thus, disrupting interactions between NRBP1 and its substrates BRI2 and BRI3 may provide a useful therapeutic strategy for AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据